Lumigan and Erythema multiforme - a phase IV clinical study of FDA data

Summary:

Erythema multiforme is reported as a side effect among people who take Lumigan (bimatoprost), especially for people who are male, 60+ old, also take Zaroxolyn, and have Erysipelas.

The phase IV clinical study analyzes which people have Erythema multiforme when taking Lumigan. It is created by eHealthMe based on reports of 20,141 people who have side effects when taking Lumigan from the FDA, and is updated regularly.

What is Lumigan?

Lumigan has active ingredients of bimatoprost. It is often used in glaucoma. eHealthMe is studying from 20,478 Lumigan users. Check the latest studies of Lumigan.

What is Erythema multiforme?

Erythema multiforme (a type of hypersensitivity reaction) is found to be associated with 1,693 drugs and 2,922 conditions by eHealthMe. Check the latest studies of Erythema multiforme.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

20,141 people reported to have side effects when taking Lumigan.
Among them, 12 people (0.06%) have Erythema multiforme.

Could Lumigan cause Erythema multiforme?

Among these 12 people:

What is the gender of people who have Erythema multiforme when taking Lumigan? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Erythema multiforme when taking Lumigan? *

What are other drugs people take besides Lumigan? *

Eplerenone: 5 people, 41.67%
Potassium Chloride: 5 people, 41.67%
Bisoprolol Fumarate: 5 people, 41.67%
Clarithromycin: 5 people, 41.67%
Fexofenadine Hydrochloride: 5 people, 41.67%
Allopurinol: 5 people, 41.67%
Ventolin: 5 people, 41.67%
Zaroxolyn: 5 people, 41.67%
Azopt: 3 people, 25.00%
Alphagan: 2 people, 16.67%

What are other side effects people have besides Erythema multiforme? *

Lichenoid Keratosis (a skin disorder described by rapid growing, reddish to brown, benign (noncancerous) lesion on the skin): 6 people, 50.00%
Nikolsky's Sign: 5 people, 41.67%
Skin Oedema (swelling of skin): 5 people, 41.67%
Rashes (redness): 3 people, 25.00%
Fever: 2 people, 16.67%
Lacrimation Increased: 2 people, 16.67%
Eyelid Oedema (eyelids are swollen and contain excessive fluid): 2 people, 16.67%
Weakness: 1 person, 8.33%
Lip Pain: 1 person, 8.33%
Lip Exfoliation: 1 person, 8.33%

What are the existing conditions these people have? *

Erysipelas (bacterial skin infection): 5 people, 41.67%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 8.33%
Prostate Cancer: 1 person, 8.33%
Ovarian Cancer Recurrent (reoccurrence of ovary cancer): 1 person, 8.33%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Lumigan and have Erythema multiforme?

- Check whether Erythema multiforme is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lumigan:

Lumigan (20,478 reports)

Browse all side effects of Lumigan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Erythema multiforme:

Erythema multiforme (1,693 drugs)

Browse all the conditions that are associated with Erythema multiforme:

Erythema multiforme (2,922 conditions)

Related publications that referenced our studies

Tognetti L, Giorgini S, Lotti T, "Erythema multiforme-like eruption from a slimming drug preparation cutaneous adverse drug reaction", Indian dermatology online journal, 2011 Jan .
Tognetti L, Giorgini S, Lotti T, "Erythema multiforme-like eruption from a slimming drug preparation cutaneous adverse drug reaction", Indian dermatology online journal, 2011 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on bimatoprost (the active ingredients of Lumigan) and Lumigan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.